Table 3.
Association of Baseline Clinical and Pathologic Characteristics of Deferred Treatment Group With Progression to Treatment After 1 Year
| Characteristic | Age-Adjusted Hazard Ratio* | 95% CI | Multivariate Hazard Ratio† | 95% CI |
|---|---|---|---|---|
| Age at diagnosis, years | ||||
| < 60 | 2.10 | 1.15 to 3.84 | 2.15 | 1.16 to 3.97 |
| 60-69 | 1.71 | 1.23 to 2.38 | 1.80 | 1.27 to 2.53 |
| 70+ | 1.00 | 1.00 | ||
| Race | ||||
| White | 1.00 | 1.00 | ||
| Non-white | 1.07 | 0.50 to 2.28 | 1.11 | 0.51 to 2.39 |
| BMI | ||||
| < 25 | 1.07 | 0.78 to 1.45 | 1.08 | 0.79 to 1.48 |
| 25+ | 1.00 | 1.00 | ||
| Stage | ||||
| T1 | 1.00 | 1.00 | ||
| T2+ | 1.49 | 1.08 to 2.07 | 1.52 | 1.09 to 2.13 |
| PSA at diagnosis, ng/mL | ||||
| < 4 | 0.29 | 0.15 to 0.56 | 0.33 | 0.17 to 0.65 |
| 4 to < 10 | 0.51 | 0.31 to 0.85 | 0.57 | 0.34 to 0.96 |
| 10-20 | 0.55 | 0.31 to 0.97 | 0.61 | 0.34 to 1.08 |
| > 20 | 1.00 | 1.00 | ||
| Gleason score | ||||
| < 6 | 0.46 | 0.29 to 0.74 | 0.50 | 0.31 to 0.80 |
| 6 | 0.64 | 0.42 to 0.96 | 0.69 | 0.45 to 1.05 |
| > 6 | 1.00 | 1.00 |
Abbreviations: BMI, body mass index; PSA, prostate-specific antigen.
*
Adjusted for age and time of diagnosis.
†
Adjusted for age, time of diagnosis, clinical stage, PSA at diagnosis, and Gleason score.